Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Immunocore Holdings (IMCR)
NASDAQ:IMCR
IMCR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$27.69 - $72.56
Previous CloseN/A
Volume28.13K
Average Volume (3M)212.24K
Market Cap
$1.48B
Enterprise Value$1.22B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.25
Next Earnings
Feb 26, 2025EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.96
Shares Outstanding50,032,770
10 Day Avg. Volume153,027
30 Day Avg. Volume212,242
Standard Deviation0.15
R-Squared0.06
Alpha-0.00543
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)9.76
Price to Cash Flow (P/CF)37.70
P/FCF Ratio27.30
Enterprise Value/Market Cap0.83
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit4.93
Enterprise Value/Ebitda-19.29
Forecast
1Y Price Target
$68.86Price Target Upside135.82% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
---
Immunocore Holdings News
PremiumCompany Announcements
Immunocore Holdings Outlines Strategic Priorities for 2025
PremiumCompany Announcements
Immunocore Holdings Strengthens Leadership with Key Appointment
---
Bulls Say, Bears Say
Bulls Say
Financial StabilityThe company has a strong cash balance with ~$820M at year-end.
HIV Treatment DevelopmentThe HIV program is nearing a key readout, showing progress in developing a potential functional cure for HIV with IMC-M113V.
KIMMTRAK Sales GrowthAnalysts expect peak global revenues for KIMMTRAK to surpass $1 billion across all indications if approved.
Bears Say
HIV Program PartnershipThe HIV update remains on track and could be important for partnering.
Investor SentimentInvestors are struggling with the catalyst set-up and the market views the next brene readouts as 'show me' type of events.
Strategic PrioritizationValue for brenetafusp in EC is being removed due to the company prioritizing other indications.
---
Ownership Overview
― Insiders
32.89% Mutual Funds
51.23% Other Institutional Investors
14.92% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
IMCR FAQ
What was Immunocore Holdings’s price range in the past 12 months?
Immunocore Holdings lowest stock price was $27.69 and its highest was $72.56 in the past 12 months.
What is Immunocore Holdings’s market cap?
Immunocore Holdings’s market cap is $1.48B.
When is Immunocore Holdings’s upcoming earnings report date?
Immunocore Holdings’s upcoming earnings report date is Feb 26, 2025 which is in 5 days.
How were Immunocore Holdings’s earnings last quarter?
Immunocore Holdings released its earnings results on Nov 06, 2024. The company reported $0.17 earnings per share for the quarter, beating the consensus estimate of -$0.343 by $0.513.
Is Immunocore Holdings overvalued?
According to Wall Street analysts Immunocore Holdings’s price is currently Undervalued.
Does Immunocore Holdings pay dividends?
Immunocore Holdings does not currently pay dividends.
What is Immunocore Holdings’s EPS estimate?
Immunocore Holdings’s EPS estimate is -0.24.
How many shares outstanding does Immunocore Holdings have?
Immunocore Holdings has 50,032,770 shares outstanding.
What happened to Immunocore Holdings’s price movement after its last earnings report?
Immunocore Holdings reported an EPS of $0.17 in its last earnings report, beating expectations of -$0.343. Following the earnings report the stock price went up 1.576%.
Which hedge fund is a major shareholder of Immunocore Holdings?
Currently, no hedge funds are holding shares in IMCR
---
Immunocore Holdings Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$68.86 (135.82% Upside)
$68.86 (135.82% Upside)
Blogger Sentiment
Bullish
IMCR Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 6.1%
Last 30 Days ▼ 6.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-58.27%
12-Months-Change
Fundamentals
Return on Equity
-12.85%
Trailing 12-Months
Asset Growth
91.47%
Trailing 12-Months
Company Description
Immunocore Holdings
Immunocore Holdings PLC is a late-stage biotechnology company engaged in the development of a novel class of TCR bispecific immunotherapies for the treatment of cancer, infectious and autoimmune diseases.
---
IMCR Stock 12 Month Forecast
Average Price Target
$68.86
▲(135.82% Upside)
Technical Analysis
Bluebird Bio
―
Fate Therapeutics
―
Karyopharm Therapeutics
―
Iovance Biotherapeutics
―
Adaptimmune Therapeutics
―
Best Analysts Covering IMCR
1 Year
1 Year Success Rate
5/12 ratings generated profit
1 Year Average Return
+6.28%
reiterated a buy rating last month
Copying Jessica Fye's trades and holding each position for 1 Year would result in 41.67% of your transactions generating a profit, with an average return of +6.28% per trade.
---